 Source: Willy Barton Shutterstock.com Spero Therapeutics NASDAQ: SPRO stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK NYSE: GSK . This deal covers the rights to tebipenem HBr, which is an antibiotic asset in late-stage development by Spero Therapeutics. 